News & Updates

Bromocriptine quick release, a medication used for Parkinson’s disease and type 2 diabetes (T2D), appears to confer cardiovascular benefits such as lower blood pressure (BP) and reduced aortic stiffness in teenagers with type 1 diabetes (T1D), according to data from the BCQR-T1D study.

Adding a once-weekly dose of semaglutide to lifestyle intervention successfully reduced body mass index (BMI) in adolescents with obesity, according to results of the phase IIIa STEP TEENS trial.

Co-treatment with methotrexate (MTX) appears to enhance response rates to pegloticase among patients with uncontrolled gout, according to a study.

Treatment with osmotic-release oral system methylphenidate falls short of reducing symptoms of attention-deficit hyperactivity disorder (ADHD) in young adult prisoners, as shown in a study.

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.